Teleflex (NYSE: TFX) has recently received a number of price target changes and ratings updates:

  • 9/25/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Stephens. They now have a $270.00 price target on the stock, up previously from $230.00.
  • 9/22/2017 – Teleflex was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $265.00 price target on the stock. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 9/19/2017 – Teleflex was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 9/18/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $251.00 price target on the stock, up previously from $238.00.
  • 9/12/2017 – Teleflex had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $253.00 price target on the stock, up previously from $230.00. They wrote, “XLRS Progressing Slowly with Some Uncertainty. Although top-line safety data from 12 patients in the Phase I/II XLRS dose escalation study did not reveal SAEs and moderate ocular inflammation was considered manageable, the combination of inter-patient and test variability has affected the ability to determine a therapeutic effect. As a result, AGTC plans to expand enrollment and follow the new patients for at least six months.””
  • 9/12/2017 – Teleflex was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $261.00 price target on the stock. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 9/9/2017 – Teleflex was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 9/8/2017 – Teleflex had its price target raised by analysts at Jefferies Group LLC from $253.00 to $270.00. They now have a “buy” rating on the stock.
  • 9/7/2017 – Teleflex was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating. They now have a $266.00 price target on the stock, up previously from $227.00.
  • 9/6/2017 – Teleflex had its “hold” rating reaffirmed by analysts at KeyCorp.
  • 9/6/2017 – Teleflex was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $274.00 price target on the stock, up previously from $220.00.
  • 9/5/2017 – Teleflex had its price target raised by analysts at Needham & Company LLC from $228.00 to $237.00. They now have a “buy” rating on the stock. They wrote, “TFX announced it is acquiring NeoTract for $725M of cash upfront and up to another $375M of revenue-based milestone payments. NeoTract has an innovative treatment for benign prostatic hyperplasia (BPH) called UroLift which offers a number of advantages to competing BPH procedures. The BPH market is large and underpenetrated with potential to reach $30B+ worldwide. TFX expects the deal to be accretive to its revenue growth, margins, and EPS by 2019.””
  • 9/1/2017 – Teleflex was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $232.00 price target on the stock. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 8/31/2017 – Teleflex was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 8/25/2017 – Teleflex was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $233.00 price target on the stock. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 8/24/2017 – Teleflex was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 8/9/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $253.00 price target on the stock, up previously from $230.00.
  • 8/9/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $238.00 price target on the stock, up previously from $220.00.
  • 8/8/2017 – Teleflex was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Teleflex Incorporated (NYSE TFX) opened at 244.25 on Wednesday. The firm has a market capitalization of $11.00 billion, a P/E ratio of 46.71 and a beta of 1.07. The stock’s 50 day moving average price is $225.61 and its 200-day moving average price is $208.48. Teleflex Incorporated has a 12 month low of $136.53 and a 12 month high of $246.67.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.13. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The firm had revenue of $528.60 million during the quarter, compared to the consensus estimate of $518.98 million. During the same period in the prior year, the firm earned $1.89 EPS. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, analysts forecast that Teleflex Incorporated will post $8.28 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Tuesday, August 15th were paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date was Friday, August 11th. Teleflex’s dividend payout ratio is presently 26.00%.

In other news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $211.75, for a total value of $42,350.00. Following the completion of the sale, the director now owns 8,080 shares of the company’s stock, valued at $1,710,940. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have sold 600 shares of company stock worth $132,408. 2.39% of the stock is currently owned by insiders.

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.